Newron Pharmaceuticals SpA (XSWX:NWRN) General and Admin. Expense: CHF4.46 Mil (TTM As of Dec. 2025)


XSWX:NWRN Newron Pharmaceuticals SpA XSWX:NWRN
64 GF Score
Price CHF11.80
GF Value CHF13.03
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA General and Admin. Expense?

Newron Pharmaceuticals SpA XSWX:NWRN -1.99% 64 General and Admin. Expense is CHF4.46 Mil as of Dec. 2025. GuruFocus rates XSWX:NWRN with a GF Score™ of 64/100 and a GF Value™ of CHF13.03 (Fairly Valued). The stock has 5 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Newron Pharmaceuticals SpA's General and Admin. Expense for the six months ended in Dec. 2025 was CHF2.10 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF4.46 Mil.

Newron Pharmaceuticals SpA General and Admin. Expense Related Terms

Newron Pharmaceuticals SpA General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA General and Admin. Expense Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.64 3.49 3.76 6.89 4.45

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 2.62 4.35 2.35 2.10
XSWX:NWRN
64GF Score
Newron Pharmaceuticals SpA XSWX:NWRN
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF4.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of CHF4.46 Mil mean?
Newron Pharmaceuticals SpA (XSWX:NWRN) has a General and Admin. Expense of CHF4.46 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's General and Admin. Expense too high?
Newron Pharmaceuticals SpA's current General and Admin. Expense is CHF4.46 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's General and Admin. Expense compare to VRTX and REGN?
Newron Pharmaceuticals SpA's General and Admin. Expense of CHF4.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current General and Admin. Expense is CHF4.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XSWX:NWRN) is currently considered Fairly Valued. The stock's GF Value™ is CHF13.03, compared to a current price of CHF11.80 — trading 9.4% below its estimated fair value. The current General and Admin. Expense is CHF4.46 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XSWX:NWRN), the current General and Admin. Expense is CHF4.46 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of CHF11.80 is trading 9.4% below its estimated GF Value™ of CHF13.03. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for XSWX:NWRN:

  • General and Admin. Expense: CHF4.46 Mil
  • GF Value™: CHF13.03 vs. price of CHF11.80 (9.4% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Other Exchanges NWRNz:UK0QOI:UKNP5:Germany
Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score

Get the complete analysis for XSWX:NWRN

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF11.80
Price
CHF13.03
GF Value